Format

Send to

Choose Destination
Trends Cancer. 2017 May;3(5):347-356. doi: 10.1016/j.trecan.2017.03.007. Epub 2017 Apr 8.

Stem Cells, Cancer, and MUSASHI in Blood and Guts.

Author information

1
Molecular Pharmacology Program and Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. Electronic address: kharasm@mskcc.org.
2
Department of Biomedical Sciences, School of Veterinary Medicine, and Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, PA 19146, USA. Electronic address: lengner@upenn.edu.

Abstract

The mammalian MSI family of RNA-binding proteins (RBPs) have important roles as oncoproteins in an array of tumor types, including leukemias, glioblastomas, and pancreatic, breast, lung, and colorectal cancers. The mammalian Msi genes, Msi1 and Msi2, have been most thoroughly investigated in two highly proliferative tissues prone to oncogenic transformation: the hematopoietic lineage and the intestinal epithelium. Despite their vast phenotypic differences, MSI proteins appear to have an analogous role in governing the stem cell compartment in both of these tissues, potentially providing a paradigm for a broader understanding of MSI function and oncogenic activities. In this review, we focus on the function of MSI in the blood and the intestine, and discuss therapeutic strategies for targeting this pathway.

KEYWORDS:

RNA binding proteins; cancer; cancer stem cells; stem cells

PMID:
28718412
PMCID:
PMC5546142
DOI:
10.1016/j.trecan.2017.03.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center